Dihydroergotamine

• Catalog No.: DB00320
• CAS Number: 6190-39-2
• M. F.: C33H37N5O5
• M. W.: 583.67738

SYNONYMS

• IUPAC name: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
• IUPAC Traditional name: dihydroergotamine
• Brand Name: Migranal; Dirgotarl; Dergotamine; Ergont; Dihydergot; Agit; Angionorm; D.H.E. 45; DET MS; Diergo; Ikaran; Verladyn; D.H.E.; DHE-45; Endophleban; Ergomimet; Ergotonin; Morena; Orstanorm; Tonopres
• Synonyms: 9,10-dihydro-ergotamine; Dihidroergotamina [INN-Spanish]; Dihydroergotamine monomethanesulfonate; Dihydroergotaminum [INN-Latin]; Dihydroergotamine mesylate; Dihydroergotamine methanesulfonate

DATABASE IDS

• PubChem CID: 10531
• CAS Number: 6190-39-2
• PubChem SID: 46507711

PROPERTIES

• Hydrophobicity(logP): 2

DETAILS

Description (English)

• Drug Groups: approved
• Description: A 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconstrictor, specifically for the therapy of migraine disorders. [PubChem]
• Indication: For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
• Pharmacology: Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT_1Da and 5-HT_1Db receptors. It also binds with high affinity to serotonin 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT_1D receptors.
• Toxicity: Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: Interpatient variable and may be dependent on the administration technique
• Half Life: 9 hours
• Protein Binding: 93% (to plasma proteins)
• Elimination: The major excretory route of dihydroergotamine is via the bile in the feces. ; Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection.
• Distribution: * 800 L
• Clearance: * 1.5 L/min
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com